Tags : IMspire150 Study

Roche Reports Results of Triple Combination Regimen in P-III IMspire150

Shots: The P-III IMspire150 study involves assessing of Tecentriq (atezolizumab) + Cotellic (cobimetinib) + Zelboraf (vemurafenib) vs PBO+ Cotellic + Zelboraf in patients with previously untreated BRAF V600 mutation-positive advanced melanoma The P-III IMspire150 study results: reduction in risk of disease worsening or death; improvement in PFS; consistent safety profile with the known profile of […]Read More